Vera Therapeutics (VERA) Q3 2026 earnings review
Vera Therapeutics starts kidney drug sales, but cash burn stays high
Vera Therapeutics recorded its first prescription drug sales while spending heavily to build its commercial team. Following conditional U.S. approval on July 7, its kidney medicine Trutakna generated $10 million in third-quarter revenue and drew about 700 patient enrollment forms. Chief executive Marshall Fordyce also reported two-year trial results showing the weekly injection cut the risk of kidney disease progression by 76%, allowing the biotechnology company to file for full U.S. approval in early November.
| Net product revenue | $10.3M first quarter on the market after July 7 approval |
|---|---|
| Patient Start Forms | ~700 received from launch through early November |
| Operating cash burn | $99M by our math in Q3; $306M used over nine months |
| Full FDA approval plan | Filed Nov 3 FDA decision expected in mid-2027 |
⚖️ Verdict: 🟢 Bullish
The story got better because the two-year clinical readout cleared the biggest hurdle to keeping the drug on the market and winning full insurance coverage. One caution: commercial launch expenses kept operating cash burn near $99 million for the quarter by our math, prompting Vera to borrow $75 million from its credit line in October, and unpaid customer bills at quarter-end exceeded total revenue.
The question now is how quickly those 700 enrollment forms turn into recurring, cash-paying prescriptions rather than free trial supply or distributor warehouse stocking. If insurers approve claims smoothly, revenue will outpace unpaid bills and narrow the cash burn; if coverage lags, the company will rely further on its credit line. Fourth-quarter revenue and accounts receivable will tell.
🐂 Bull Case
First Quarter on the Market Brought 700 Patient Forms
Vera Therapeutics develops medicines for autoimmune kidney diseases. On July 7, 2026, U.S. regulators granted accelerated approval to its first commercial product, Trutakna, a once-weekly at-home injection for adults with primary immunoglobulin A nephropathy (IgAN), a chronic disease that damages kidney filters. Chief executive Marshall Fordyce said the drug has the "potential to become a foundational therapy in IgAN".
In the nearly three months of sales during the third quarter, the biotechnology group booked $10.3 million in net product revenue. Doctors also submitted about 700 Patient Start Forms, the paperwork needed to enroll patients and check insurance, through early November. Because roughly 75% of the 160,000 diagnosed U.S. patients have commercial insurance, early doctor interest gives the sales force a large pool of prescriptions to convert.
What to watch: fourth-quarter net product revenue and any update on Patient Start Forms. Faster revenue growth than form growth would show that initial enrollments are turning into recurring paid refills.
Two-Year Trial Data Cleared the Full Approval Hurdle
Trutakna is currently sold under conditional approval based on reducing protein in the urine, so keeping it on the market requires proving it protects long-term kidney function. During the quarter, the company presented final two-year results from its pivotal ORIGIN 3 study showing "stabilization of kidney function and a 76% reduction in risk of composite kidney disease progression versus placebo through two years".
- Annual kidney filtration decline (eGFR slope): -0.6 units per year on Trutakna versus -5.6 on placebo, a 5.0-unit advantage
- Infection rate in trials: 32% for Trutakna patients versus 28% on placebo
- Injection site reactions: 30% on Trutakna versus 5% on placebo
Backed by those results, the kidney drug maker filed its supplemental application for full U.S. approval on November 3 and plans a European filing in the first quarter of 2027. Separately, early results from its Phase 2 PIONEER trial "support the continued investigation of atacicept in antibody-mediated glomerular diseases". Full approval matters because it removes regulatory risk and helps convince hesitant insurers to pay.
What to watch: FDA acceptance of the supplemental filing and the regulator's decision expected in mid-2027. Full approval would remove the conditional label warning that long-term kidney benefit is unproven.
🐻 Bear Case
Cash Burn Near $100M Prompted a New Debt Draw
"Our transition to a commercial-stage company marks a new chapter for Vera, as we deliver on our commitment to people living with IgAN," Fordyce said. Building a commercial sales infrastructure while running clinical trials is expensive, and the first quarter of drug sales covered less than one-tenth of the company's total operating bill.
Selling, general and administrative expenses more than doubled from a year ago to $61.4 million, driven by launch hiring and marketing. Nine-month operating cash use reached $305.9 million, "primarily due to increased investment in the commercial launch of TRUTAKNA". By our math, that puts third-quarter operating cash burn at $99.1 million, barely changed from $100.3 million in the second quarter. To pad its $384.0 million cash balance, the drugmaker borrowed $75 million from its credit line in late October.
What to watch: fourth-quarter operating cash burn against product revenue growth. If quarterly cash use stays near $100 million, the company will have to draw more of its remaining $350 million loan facility and pay higher interest costs.
Unpaid Bills Exceeded Sales While Conversion Rates Stayed Hidden
Commercial chief Matt Skelton pointed to roughly 700 Patient Start Forms received since July and said the team is "encouraged by the payer coverage policies taking shape". A start form only begins the insurance check, however, and Vera did not disclose how many of those 700 forms actually turned into paid, shipped prescriptions.
Meanwhile, the balance sheet shows $12.0 million in accounts receivable, which is money owed by drug distributors and specialty pharmacies. By our math, unpaid customer bills equaled 116.6% of the quarter's $10.3 million in net product revenue. That means Vera collected almost no cash from its initial drug shipments before September 30, and revenue may reflect initial warehouse stocking by distributors rather than patient refills.
What to watch: accounts receivable compared with net product revenue in the fourth quarter. If unpaid bills drop well below quarterly sales, distributors are paying on normal schedules and selling through to patients.
👓 Other Themes
Inventory Accounting Cut Research Spending by $19 Million
Vera's operating loss narrowed from $112.5 million in the second quarter to $95.7 million in the third, helped by an accounting rule change after drug approval. Research and development spending fell by $18.8 million from last quarter to $41.3 million because commercial manufacturing bills, previously expensed as research, "have been capitalized as inventory since its accelerated approval on July 7, 2026".
💲 Other KPIs
In its first quarter of commercial sales, Vera recorded $3.3 million in cost of sales against $10.3 million in product revenue, leaving a 67.9% gross margin by our math. The balance sheet also added $7.1 million in inventory and $20.5 million in net intangible assets following July's regulatory approval.
Cash and marketable securities fell by $115.1 million from the second quarter as launch spending continued. In late October, the biotech company drew $75 million from its credit facility, lifting pro forma cash to $459.0 million and increasing long-term debt from $75.4 million at quarter-end.
The average share count rose 13.0% from a year ago, up from 63.8 million shares in the third quarter of 2025, following late-2025 equity financing. The higher share count kept net loss per share growth to 3.2%, at $1.30, even though total net loss widened by 16.7% to $93.7 million.
🔮 Guidance
Unchanged. The company narrowed its target window for full U.S. regulatory approval to mid-2027 after submitting its supplemental application on November 3, 2026. That matches its earlier target of 2027 and assumes standard regulatory review timelines following the positive two-year ORIGIN 3 kidney function readout.
New. Management plans to submit an application for standard marketing authorization in Europe during the first quarter of 2027. Because Vera retains all global commercial rights to Trutakna, a European filing opens its first path to sales outside the United States.
Unchanged in total capacity. Up to $350 million remains available to borrow after the company drew $75 million in late October from the $425 million credit line. Accessing the rest depends on meeting undisclosed conditions under the loan agreement.
❓ Key Questions
How many Patient Start Forms turned into paid shipments?
Vera reported roughly 700 enrollment forms since launch and $10.3 million in sales, but did not say how many patients are on paid drug versus free bridge supply or waiting for insurance approval.
How much of Q3 revenue came from distributor inventory stocking?
Accounts receivable ended the quarter at $12.0 million, exceeding the $10.3 million in net revenue. Knowing how many weeks of supply sit in specialty pharmacies will show true patient demand.
What milestones unlock the remaining $350 million credit facility?
The company burned $99.1 million of operating cash in Q3 by our math and drew $75 million in debt in October. Investors need to know the revenue or regulatory conditions required for future draws.
Why did initial gross margin start at 68%?
Cost of sales was 32.1% of net revenue even though pre-approval manufacturing costs were previously expensed as research. Management did not break down how royalties, amortizations or small-batch manufacturing affected cost of sales.